Archiv der Pharmazie

Journal Information
ISSN / EISSN : 03656233 / 15214184
Current Publisher: Wiley (10.1002)
Total articles ≅ 45,740
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Kodam Sujatha, Naidu Babu Ommi, Anwita Mudiraj, Phanithi Prakash Babu, Rajeswar Rao Vedula
Published: 11 October 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900079

The publisher has not yet granted permission to display this abstract.
Halil I. Ciftci, Nilüfer Bayrak, Hatice Yıldırım, Mahmut Yıldız, Mohamed O. Radwan, Masami Otsuka, Mikako Fujita, Amaç F. Tuyun
Published: 11 October 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900170

The publisher has not yet granted permission to display this abstract.
Sangeetha Meenakshisundaram, Manoj Manickam, Thanigaimalai Pillaiyar
Published: 9 October 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900011

Abstract:Dimerization of proteins/receptors plays a critical role in various cellular processes, including cell proliferation and differentiation. Therefore, targeting such dimeric proteins/receptors by dimeric small molecules could be a potential therapeutic approach to treating various diseases, including inflammation‐associated diseases like cancer. A novel series of bis‐imidazoles (13–18) and bis‐imidazo[1,2‐a]pyridines (19–28) were designed and synthesized from Schiff base dimers (1–12) for their anticancer activities. All the synthesized compounds were screened for anticancer activities against three cancer cell lines, including cervical (HeLa), breast (MDA‐MB‐231), and renal cancer (ACHN). From structure–activity relationship studies, imidazo[1,2‐a]pyridines (19–28) showed remarkable cytotoxic activities, with compounds 19 and 24 showing the best inhibitory activities against all three cell lines. Especially, both 19 and 24 were very effective against the breast cancer cell line (19, GI50 = 0.43 µM; 24, GI50 = 0.3 µM), exceeding the activity of the control adriamycin (GI50 = 0.51 µM). The in vivo anticancer activity results of compounds 19 and 24 were comparable with those of the animals treated with the standard drug tamoxifen. Therefore, the dimeric imidazo[1,2‐a]pyridine scaffold could serve as a potential lead for the development of novel anticancer agents.
Abdel‐Ghany A. El‐Helby, Helmy Sakr, Ibrahim H. Eissa, Ahmed A. Al‐Karmalawy, Khaled El‐Adl
Published: 9 October 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900178

The publisher has not yet granted permission to display this abstract.
Published: 8 October 2019
by Wiley
Archiv der Pharmazie, Volume 352; doi:10.1002/ardp.201970019

Published: 8 October 2019
by Wiley
Archiv der Pharmazie, Volume 352; doi:10.1002/ardp.201970020

Ferhat Türker, Canbolat Gürses, Duygu Barut Celepci, Aydın Aktaş, Burhan Ateş, Yetkin Gök
Published: 4 October 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900187

The publisher has not yet granted permission to display this abstract.
Ufuk Atmaca, Shahla Daryadel, Parham Taslimi, Murat Çelik, Ilhami Gülçin
Published: 23 September 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900200

The publisher has not yet granted permission to display this abstract.
Muhammad Iftikhar, Shahnawaz, Muhammad Saleem, Naheed Riaz, Aziz‐ Ur‐ Rehman, Ishtiaq Ahmed, Jameel Rahman, Muhammad Ashraf, Muhammad S. Sharif, Shafi U. Khan, et al.
Published: 23 September 2019
by Wiley
Archiv der Pharmazie; doi:10.1002/ardp.201900095

The publisher has not yet granted permission to display this abstract.